An Open-Label, Randomized, Adaptive, Two-Arm, Multicenter Trial to Evaluate Pharmacokinetics And Pharmacodynamics of Two Doses of Oseltamivir (Tamiflu) in The Treatment Of Influenza in Immunocompromised Children Less Than 13 Years Of Age, With Confirmed Influenza Infection

Trial Profile

An Open-Label, Randomized, Adaptive, Two-Arm, Multicenter Trial to Evaluate Pharmacokinetics And Pharmacodynamics of Two Doses of Oseltamivir (Tamiflu) in The Treatment Of Influenza in Immunocompromised Children Less Than 13 Years Of Age, With Confirmed Influenza Infection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs Oseltamivir (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 06 Apr 2018 Planned End Date changed from 31 May 2018 to 31 May 2019.
    • 06 Apr 2018 Planned primary completion date changed from 31 May 2018 to 31 May 2019.
    • 03 Nov 2017 Planned End Date changed from 26 May 2018 to 31 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top